论文部分内容阅读
目的明确白花香莲解毒方联合阿德福韦酯治疗慢性乙型肝炎(CHB)肝纤维化患者的临床疗效。方法选择118例CHB患者随机分为治疗组(60例)和对照组(58例),治疗前后检测患者血清透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、层粘连蛋白(LN)、Ⅳ型胶原(Ⅳ-C)以及总胆红素(TBIL)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、HBV-DNA水平。结果治疗24周后,治疗组患者血清HA、LN、Ⅳ-C、HBV-DNA水平与治疗前及对照组比较,均显著降低,具有统计学意义(P<0.05);而两组患者PCⅢ、TBIL、ALT、AST的下降幅度无显著性差异(P>0.05)。结论白花香莲解毒方联合阿德福韦酯联合治疗慢乙肝肝纤维化患者,不仅具有较好的保护肝细胞、抗乙肝病毒作用,而且还有一定的抗肝纤维化作用。
Objective To investigate the clinical efficacy of Baihua Xianglian detoxification combined with adefovir dipivoxil in the treatment of patients with chronic hepatitis B (CHB) liver fibrosis. Methods A total of 118 patients with CHB were randomly divided into treatment group (60 cases) and control group (58 cases). Serum hyaluronic acid (HA), type Ⅲ procollagen (PC Ⅲ), laminin (LN) (Ⅳ-C) and total bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), HBV-DNA levels. Results After treatment for 24 weeks, the levels of serum HA, LN, IV-C and HBV-DNA in the treatment group were significantly lower than those before treatment and in the control group (P <0.05) TBIL, ALT, AST decreased no significant difference (P> 0.05). Conclusion Baihuaxianlian detoxification combined with adefovir dipivoxil in the treatment of chronic hepatitis B patients with liver fibrosis, not only has a good protection of liver cells, anti-hepatitis B virus effect, but also a certain anti-liver fibrosis.